SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

First Patient Dosed in IntelGenx's Resumed 'BUENA' Montelukast VersaFilm Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

01/21/2022 | 09:22am EDT

SAINT LAURENT, Quebec - IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) ('IntelGenx' or the 'Company'), a leader in pharmaceutical films, announced that patient dosing has resumed in the ongoing Phase 2a ('BUENA') clinical trial in patients with mild to moderate Alzheimer's Disease ('AD') under a previously amended protocol using higher doses of Montelukast VersaFilm.

'Resumption of patient dosing after a COVID-related interruption of the study of over one year is a significant milestone for this novel drug repurposing program, and we look forward to the BUENA trial producing valuable data that will provide more complete insight into the safety, feasibility, tolerability and efficacy of Montelukast VersaFilm in patients with mild to moderate AD,' commented Dr. Horst Zerbe, IntelGenx's CEO.

'A significant unmet medical need remains for safe and effective treatments for mild to moderate AD,' said Dr. Ludwig Aigner, a member of IntelGenx'sScientific Advisory Board. 'We believe that Montelukast VersaFilm has the potential to be disease-modifying, and we are excited to have resumed patient dosing in this proof of concept trial.'

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx's superior film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx's innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit

Forward Looking Statements

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words 'may,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'could,' 'would,' and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading 'Risk Factors' in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at, and also filed with Canadian securities regulatory authorities at IntelGenx assumes no obligation to update any such forward-looking statements.



Stephen Kilmer

Investor Relations

T: (647) 872-4849


Andre Godin, CPA, CA

President and CFO

IntelGenx Corp.

T: (514) 331-7440 ext 203


(C) 2022 Electronic News Publishing, source ENP Newswire

05/13IntelGenx Technologies Reports First Quarter 2022 Financial Results
05/12INTELGENX : Q1 Earnings Snapshot
05/12TRANSCRIPT : IntelGenx Technologies Corp., Q1 2022 Earnings Call, May 12, 2022
05/12IntelGenx Technologies First-Quarter Loss Widens as Sales Fall 17%
05/12INTELGENX TECHNOLOGIES CORP. : Management's Discussion and Analysis of Financial Condition..
05/12INTELGENX BRIEF : Net comprehensive loss was US$3.0 million, compared to $2.3 million in Q..
05/12INTELGENX BRIEF : Revenue was US$237,000, compared to $286,000 in the 2021 first quarter
05/12IntelGenx Technologies Corp. Reports Earnings Results for the First Quarter Ended March..
05/12IntelGenx Reports First Quarter 2022 Financial Results
05/11INTELGENX TECHNOLOGIES CORP. : Submission of Matters to a Vote of Security Holders (form 8..
More news
Financials (USD)
Net income
Net Debt
P/E ratio
Capitalization 48,2 M 48,2 M -
EV / Sales -1
EV / Sales 0
Nbr of Employees 50
Free-Float 74,8%
Duration : Period :
IntelGenx Technologies Corp. Technical Analysis Chart | IGXT | US45822R1014 | MarketScreener
Income Statement Evolution
Managers and Directors
Horst G. Zerbe Chairman & Chief Executive Officer
André Godin President & Chief Financial Officer
Nadine Paiement Vice President-Research & Development
Rodolphe Obeid Chief Operating Officer
Bernd Josef Melchers Independent Director